Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41

The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by targeting the highly conserved heptad repeat 1 (HR1) of gp41, which is transiently exposed during HIV-1 entry. Here we present the crystal structure of the HK20 Fab in complex with a gp41 mimetic 5-Helix at 2.3 Å resolution. HK20 employs its heavy chain CDR H2 and H3 loops to bind into a conserved hydrophobic HR1 pocket that is occupied by HR2 residues in the gp41 post fusion conformation. Compared to the previously described HR1-specific mAb D5, HK20 approaches its epitope with a different angle which might favor epitope access and thus contribute to its higher neutralization breadth and potency. Comparison of the neutralization activities of HK20 IgG, Fab and scFv employing both single cycle and multiple cycle neutralization assays revealed much higher potencies for the smaller Fab and scFv over IgG, implying that the target site is difficult to access for complete antibodies. Nevertheless, two thirds of sera from HIV-1 infected individuals contain significant titers of HK20-inhibiting antibodies. The breadth of neutralization of primary isolates across all clades, the higher potencies for C-clade viruses and the targeting of a distinct site as compared to the fusion inhibitor T-20 demonstrate the potential of HK20 scFv as a therapeutic tool.

[1]  Q. Sattentau,et al.  International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II , 2009, PloS one.

[2]  D. Burton,et al.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.

[3]  D. Montefiori,et al.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates , 2010, Proceedings of the National Academy of Sciences.

[4]  Felix Campelo,et al.  Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions , 2010, PLoS pathogens.

[5]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[6]  J. Condra,et al.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 , 2009, mAbs.

[7]  J. Anglister,et al.  Peptides in the treatment of AIDS. , 2009, Current opinion in structural biology.

[8]  G. Melikyan,et al.  HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes , 2009, Cell.

[9]  Q. Sattentau,et al.  International Network for Comparison of HIV Neutralization Assays: The NeutNet Report , 2009, PloS one.

[10]  J. Condra,et al.  Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. , 2008, AIDS research and human retroviruses.

[11]  R. Ptak,et al.  Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor , 2008, Journal of Biological Chemistry.

[12]  A. Koné,et al.  Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates , 2008, AIDS.

[13]  D. Richman,et al.  Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. , 2008, Virology.

[14]  S. Harrison Viral membrane fusion , 2008, Nature Structural &Molecular Biology.

[15]  J. Sodroski,et al.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.

[16]  P. Gagnon,et al.  Purification of IgM Monoclonal Antibodies : Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology , 2008 .

[17]  C. Bewley,et al.  A Monoclonal Fab Derived from a Human Nonimmune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse Human Immunodeficiency Virus Type 1 Strains , 2007, Journal of Virology.

[18]  F. Buonaguro,et al.  Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.

[19]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[20]  Winfried Weissenhorn,et al.  Virus membrane fusion , 2007, FEBS Letters.

[21]  Kevin Harris,et al.  Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery , 2007, J. Comput. Aided Mol. Des..

[22]  H. Katinger,et al.  Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. , 2007, Biochemistry.

[23]  D. Dimitrov,et al.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. , 2006, Biochemical and biophysical research communications.

[24]  Feng Gao,et al.  Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.

[25]  Rebecca Hoh,et al.  Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis , 2006, Journal of acquired immune deficiency syndromes.

[26]  M. Luftig,et al.  Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody , 2006, Nature Structural &Molecular Biology.

[27]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[28]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[29]  C. Bewley,et al.  Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. , 2005, Journal of molecular biology.

[30]  Gennaro Ciliberto,et al.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[32]  Brett D. Welch,et al.  Steric Accessibility of the HIV-1 gp41 N-trimer Region* , 2005, Journal of Biological Chemistry.

[33]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[34]  W. Weissenhorn,et al.  Class I and class II viral fusion protein structures reveal similar principles in membrane fusion (Review) , 2004, Molecular membrane biology.

[35]  Karsten Suhre,et al.  ElNémo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement , 2004, Nucleic Acids Res..

[36]  Shibo Jiang,et al.  Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes , 2004, Journal of Virology.

[37]  Michael Greenberg,et al.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.

[38]  C. Bewley,et al.  Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion* , 2003, Journal of Biological Chemistry.

[39]  Samuel K Sia,et al.  Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Abraham Pinter,et al.  Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.

[41]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[42]  G. Melikyan,et al.  Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.

[43]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[44]  Stuart L. Schreiber,et al.  Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements , 1999, Nature Structural Biology.

[45]  Anastassis Perrakis,et al.  Automated protein model building combined with iterative structure refinement , 1999, Nature Structural Biology.

[46]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[47]  P. S. Kim,et al.  Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. , 1998, Journal of molecular biology.

[48]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[49]  A. Gronenborn,et al.  Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.

[50]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[51]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[52]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[53]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[54]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[55]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[56]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[57]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[58]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[59]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[60]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[61]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[63]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.